Teva Pharmaceutical Industries Ltd. reports approval of the generic equivalent to Evista® (raloxifene) tablets, 60 mg, in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Teva will begin shipping the product within the next 30 days.

Source: Teva Pharmaceutical Industries Ltd.

In other news, Teva announced  the commercial launch of Adasuve® (loxapine) inhalation powder 10 mg, an orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Adasuve® is administered through Alexza Pharmaceuticals’ proprietary Staccato® single-use, hand-held drug-delivery technology system. This new drug-device combination product provides systemic delivery by inhalation of a thermally-generated aerosol of loxapine, a first generation antipsychotic, to the lung. Teva licensed the US commercial rights to Adasuve in May 2013 from Alexza Pharmaceuticals, inventor and developer of the Staccato® system and of Adasuve ®. Under the terms of the license and supply agreement, Teva is responsible for all US commercial and clinical activities, including US postapproval clinical studies. Alexza is responsible for manufacturing and supplying Adasuve® to Teva for commercial sales and clinical trials.

Source: Teva Pharmaceutical Industries Ltd.